NASDAQ:CYTX - Cytori Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.24 0.00 (0.00 %)
(As of 03/26/2019 03:53 AM ET)
Previous Close$0.2449
Today's Range$0.2355 - $0.2497
52-Week Range$0.22 - $3.20
Volume763,475 shs
Average Volume575,569 shs
Market Capitalization$3.23 million
P/E Ratio-0.04
Dividend YieldN/A
Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:CYTX



Sales & Book Value

Annual Sales$2.69 million
Book Value$2.25 per share


Net Income$-22,680,000.00
Net Margins-366.48%


Market Cap$3.23 million
Next Earnings Date3/28/2019 (Estimated)

Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Shares of Cytori Therapeutics reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.09. The biotechnology company had revenue of $1.56 million for the quarter, compared to analysts' expectations of $2.50 million. Cytori Therapeutics had a negative net margin of 366.48% and a negative return on equity of 202.61%. View Cytori Therapeutics' Earnings History.

When is Cytori Therapeutics' next earnings date?

Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for Cytori Therapeutics.

What price target have analysts set for CYTX?

2 analysts have issued 12 month target prices for Cytori Therapeutics' shares. Their predictions range from $5.00 to $20.00. On average, they expect Cytori Therapeutics' share price to reach $12.50 in the next year. This suggests a possible upside of 5,002.0% from the stock's current price. View Analyst Price Targets for Cytori Therapeutics.

What is the consensus analysts' recommendation for Cytori Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytori Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytori Therapeutics.

What are Wall Street analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (1/15/2019)
  • 2. HC Wainwright analysts commented, "Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models." (9/18/2018)
  • 3. Maxim Group analysts commented, "We are downgrading CYTX shares to and removing our price target (prior $3). Our fundamental view around the company’s key programs of 0918 (liposomal doxorubicin) and cell therapy (scleroderma, stress urinary incontinence) are unchanged, but capital constraints remain, and are an increasing concern." (8/15/2018)

Has Cytori Therapeutics been receiving favorable news coverage?

Media coverage about CYTX stock has trended somewhat negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytori Therapeutics earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future.

Are investors shorting Cytori Therapeutics?

Cytori Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 771,270 shares, an increase of 48.2% from the February 15th total of 520,260 shares. Based on an average daily trading volume, of 740,707 shares, the short-interest ratio is currently 1.0 days. Currently, 6.1% of the company's stock are sold short. View Cytori Therapeutics' Current Options Chain.

Who are some of Cytori Therapeutics' key competitors?

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Micron Technology (MU), BCE (BCE), Exelixis (EXEL), OHR Pharmaceutical (OHRP), Synergy Pharmaceuticals (SGYP), Athersys (ATHX), Celldex Therapeutics (CLDX), Onconova Therapeutics (ONTX), BIOLINERX LTD/S (BLRX) and Opko Health (OPK).

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:
  • Dr. Marc H. Hedrick, CEO, Pres & Director (Age 56)
  • Mr. Tiago M. Girão, CFO, Sr. VP of Operations & Sec. (Age 40)
  • Dr. John K. Fraser Ph.D., Chief Scientist (Age 58)
  • Mr. Russ Havranek, VP of Global Marketing

Who are Cytori Therapeutics' major shareholders?

Cytori Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Barclays PLC (0.76%). Company insiders that own Cytori Therapeutics stock include Ag Postfinance and Bank Sa Swissquote. View Institutional Ownership Trends for Cytori Therapeutics.

Which institutional investors are buying Cytori Therapeutics stock?

CYTX stock was acquired by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Cytori Therapeutics.

How do I buy shares of Cytori Therapeutics?

Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of CYTX stock can currently be purchased for approximately $0.2450.

How big of a company is Cytori Therapeutics?

Cytori Therapeutics has a market capitalization of $3.23 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($6.50) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.

What is Cytori Therapeutics' official website?

The official website for Cytori Therapeutics is

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]

MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  370 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  607
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel